Merck KGAA Returns PKU Drugs To BioMarin To Focus On Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck' cancer pipeline includes a potential first-in-class bi-functional immunotherapy; BioMarin anticipates taking back Kuvan commercial activities in the next 6-12 months and initiating talks with regulators over Peg-Pal's path forward.